NASDAQ:AXSM - Axsome Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $3.15 +0.05 (+1.61 %) (As of 07/20/2018 04:00 PM ET)Previous Close$3.10Today's Range$3.10 - $3.2052-Week Range$2.05 - $6.45Volume91,479 shsAverage Volume267,802 shsMarket Capitalization$80.91 millionP/E Ratio-2.50Dividend YieldN/ABeta-0.3 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation. AXS-02 is also in the Phase III clinical trial in knee osteoarthritis associated with bone marrow lesions pursuant to a special protocol assessment and in chronic low back pain associated with Modic changes. AXS-07 is in Phase I clinical trial for the acute treatment of migraine. AXS-06 is also in Phase I clinical trial for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of nonsteroidal anti-inflammatory drug associated gastric ulcers. AXS-09 is a novel, oral medicine combination of esbupropion and dextromethorphan, which is in Phase I clinical trial. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase II trial in smoking cessation. It has operations in the United States and Australia. The company was founded in 2012 and is based in New York, New York. Receive AXSM News and Ratings via Email Sign-up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:AXSM CUSIPN/A Webaxsome.com Phone212-332-3241 Debt Debt-to-Equity Ratio0.47 Current Ratio2.95 Quick Ratio2.95 Price-To-Earnings Trailing P/E Ratio-2.50 Forward P/E Ratio-2.92 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$0.66 per share Price / Book4.77 Profitability EPS (Most Recent Fiscal Year)($1.24) Net Income$-28,940,000.00 Net MarginsN/A Return on Equity-145.83% Return on Assets-74.32% Miscellaneous Employees25 Outstanding Shares25,680,000Market Cap$80.91 Axsome Therapeutics (NASDAQ:AXSM) Frequently Asked Questions What is Axsome Therapeutics' stock symbol? Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM." How were Axsome Therapeutics' earnings last quarter? Axsome Therapeutics Inc (NASDAQ:AXSM) released its quarterly earnings results on Tuesday, May, 8th. The company reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.09. View Axsome Therapeutics' Earnings History. When is Axsome Therapeutics' next earnings date? Axsome Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Axsome Therapeutics. What price target have analysts set for AXSM? 4 analysts have issued 12-month price objectives for Axsome Therapeutics' stock. Their forecasts range from $10.00 to $31.00. On average, they anticipate Axsome Therapeutics' share price to reach $17.50 in the next year. This suggests a possible upside of 455.6% from the stock's current price. View Analyst Ratings for Axsome Therapeutics. What is the consensus analysts' recommendation for Axsome Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Are investors shorting Axsome Therapeutics? Axsome Therapeutics saw a increase in short interest in the month of June. As of June 29th, there was short interest totalling 1,804,508 shares, an increase of 103.1% from the June 15th total of 888,345 shares. Based on an average daily trading volume, of 237,343 shares, the days-to-cover ratio is presently 7.6 days. Currently, 10.9% of the company's stock are sold short. View Axsome Therapeutics' Current Options Chain. Who are some of Axsome Therapeutics' key competitors? Some companies that are related to Axsome Therapeutics include Seres Therapeutics (MCRB), Achaogen (AKAO), Sienna Biopharmaceuticals (SNNA), Marinus Pharmaceuticals (MRNS), Catalyst Pharmaceuticals (CPRX), Innate Pharma (IPHYF), Minerva Neurosciences (NERV), Avid Bioservices (CDMO), Kezar Life Sciences (KZR), Kala Pharmaceuticals (KALA), Tyme Technologies (TYME), Corbus Pharmaceuticals (CRBP), Zafgen (ZFGN), Corvus Pharmaceuticals (CRVS) and Corium International (CORI). Who are Axsome Therapeutics' key executives? Axsome Therapeutics' management team includes the folowing people: Dr. Herriot Tabuteau M.D., Founder, Chairman, CEO & Pres (Age 50)Mr. Nick Pizzie, CFO & Principal Accounting Officer (Age 43)Mr. Mark Jacobson, Sr. VP of Operations & Sec. (Age 35)Dr. Robert Niecestro Ph.D., VP of Clinical & Regulatory (Age 67)Dr. Cedric O'Gorman M.D., MBA, Sr. VP of Clinical Devel. & Medical Affairs (Age 43) When did Axsome Therapeutics IPO? (AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager. Has Axsome Therapeutics been receiving favorable news coverage? News headlines about AXSM stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Axsome Therapeutics earned a coverage optimism score of 0.16 on Accern's scale. They also gave media stories about the company an impact score of 46.25 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days. Who are Axsome Therapeutics' major shareholders? Axsome Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Alethea Capital Management LLC (1.05%). View Institutional Ownership Trends for Axsome Therapeutics. Which institutional investors are buying Axsome Therapeutics stock? AXSM stock was acquired by a variety of institutional investors in the last quarter, including Alethea Capital Management LLC. View Insider Buying and Selling for Axsome Therapeutics. How do I buy shares of Axsome Therapeutics? Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Axsome Therapeutics' stock price today? One share of AXSM stock can currently be purchased for approximately $3.15. How big of a company is Axsome Therapeutics? Axsome Therapeutics has a market capitalization of $80.91 million. The company earns $-28,940,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. Axsome Therapeutics employs 25 workers across the globe. How can I contact Axsome Therapeutics? Axsome Therapeutics' mailing address is 25 BROADWAY 9TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-332-3241. MarketBeat Community Rating for Axsome Therapeutics (NASDAQ AXSM)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 165 (Vote Outperform)Underperform Votes: 147 (Vote Underperform)Total Votes: 312MarketBeat's community ratings are surveys of what our community members think about Axsome Therapeutics and other stocks. Vote "Outperform" if you believe AXSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXSM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/20/2018 by MarketBeat.com StaffFeatured Article: What are CEFs?